Vertex Pharmaceuticals, Inc. [VRTX] stock is trading at $502.60, up 0.89%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VRTX shares have gain 2.50% over the last week, with a monthly amount glided 7.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] stock has seen the most recent analyst activity on June 27, 2024, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $545. Previously, Evercore ISI upgraded its rating to Outperform on April 11, 2024, and kept the price target unchanged to $438. On February 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $515 on the stock. Evercore ISI downgraded its rating to a In-line and increased its price target to $438 on February 06, 2024. Bernstein downgraded its rating to a Mkt Perform. Robert W. Baird downgraded its rating to Underperform for this stock on January 31, 2024, but kept the price target unchanged to $325. In a note dated January 31, 2024, Maxim Group downgraded an Hold rating on this stock.
Vertex Pharmaceuticals, Inc. [VRTX] stock has fluctuated between $340.20 and $503.99 over the past year. Currently, Wall Street analysts expect the stock to reach $342.9 within the next 12 months. Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] shares were valued at $502.60 at the most recent close of the market. An investor can expect a potential drop of -31.77% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] reported sales of 10.17B for the trailing twelve months, which represents a growth of 14.21%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.47%, and Net Profit Margin reading is 0.39%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.24 and Total Capital is 0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 498.75 points at the first support level, and at 494.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 506.30, and for the 2nd resistance point, it is at 510.00.
Ratios To Look Out For
For context, Vertex Pharmaceuticals, Inc.’s Current Ratio is 3.50. Further, the Quick Ratio stands at 3.29, while the Cash Ratio is 2.41. Considering the valuation of this stock, the price to sales ratio is 12.75, the price to book ratio is 7.00 and price to earnings (TTM) ratio is 32.61.
Transactions by insiders
Recent insider trading involved Kewalramani Reshma, Officer, that happened on Jul 30 ’24 when 15202.0 shares were purchased. EVP and CMO, Bozic Carmen completed a deal on Jul 24 ’24 to sell 2280.0 shares. Meanwhile, CEO & President Kewalramani Reshma sold 15202.0 shares on Jul 22 ’24.
